JP2022515650A5 - - Google Patents

Info

Publication number
JP2022515650A5
JP2022515650A5 JP2021538205A JP2021538205A JP2022515650A5 JP 2022515650 A5 JP2022515650 A5 JP 2022515650A5 JP 2021538205 A JP2021538205 A JP 2021538205A JP 2021538205 A JP2021538205 A JP 2021538205A JP 2022515650 A5 JP2022515650 A5 JP 2022515650A5
Authority
JP
Japan
Prior art keywords
composition according
compound
subject
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/069059 external-priority patent/WO2020142486A1/en
Publication of JP2022515650A publication Critical patent/JP2022515650A/ja
Publication of JP2022515650A5 publication Critical patent/JP2022515650A5/ja
Pending legal-status Critical Current

Links

JP2021538205A 2018-12-31 2019-12-31 キナーゼ阻害剤化合物及び組成物ならびに使用方法 Pending JP2022515650A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862786991P 2018-12-31 2018-12-31
US62/786,991 2018-12-31
PCT/US2019/069059 WO2020142486A1 (en) 2018-12-31 2019-12-31 Kinase inhibitor compounds and compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2022515650A JP2022515650A (ja) 2022-02-21
JP2022515650A5 true JP2022515650A5 (cg-RX-API-DMAC10.html) 2023-01-11

Family

ID=71407427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538205A Pending JP2022515650A (ja) 2018-12-31 2019-12-31 キナーゼ阻害剤化合物及び組成物ならびに使用方法

Country Status (7)

Country Link
US (1) US20220064146A1 (cg-RX-API-DMAC10.html)
EP (1) EP3906028A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022515650A (cg-RX-API-DMAC10.html)
CN (1) CN113543783A (cg-RX-API-DMAC10.html)
AU (1) AU2019418800A1 (cg-RX-API-DMAC10.html)
CA (1) CA3124353A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020142486A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
JPWO2023008470A1 (cg-RX-API-DMAC10.html) * 2021-07-28 2023-02-02
TW202513069A (zh) 2023-07-21 2025-04-01 美商冰洲石生物科技公司 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301123A (en) * 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US20130102627A1 (en) * 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
KR102006749B1 (ko) * 2011-08-19 2019-08-02 디악쏘니 Dyrk1 억제제 및 이의 용도
SG11201406584TA (en) * 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
SI3057959T1 (en) * 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
AU2016315881B2 (en) * 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US11279703B2 (en) * 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
EA201992676A1 (ru) * 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов

Similar Documents

Publication Publication Date Title
JP2021518413A5 (cg-RX-API-DMAC10.html)
JP2022515652A5 (cg-RX-API-DMAC10.html)
US10383881B2 (en) 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
US11066419B2 (en) 1H-pyrrole-2,5-dione compounds and methods of using same
US9744169B2 (en) Compounds for treatment of fibrosis diseases
RU2638802C2 (ru) Применение антагонистов cxcr4
RU2008142360A (ru) Производные амидов и их применение для лечения нарушений, связанных с белком g
JP2021510153A5 (cg-RX-API-DMAC10.html)
JP2021518413A (ja) キナーゼ阻害剤化合物及び組成物ならびに使用方法
CA2942753A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
DK2930167T3 (en) INDOLINO DERIVATIVE AS A TYROSINKINASE INHIBITOR
AU2023201216A1 (en) Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition
US20230234935A1 (en) Kinase inhibitor compounds and compositions and methods of use
AU2018204290A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
KR102596837B1 (ko) 체세포로부터 췌장 베타 세포를 직접 분화시키는 방법 및 분화 조성물
MX2008016083A (es) Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3.
JP2016531111A (ja) 代謝疾患を処置するためのppar節約化合物
CN113543783A (zh) 激酶抑制剂化合物和组合物及使用方法
US7968535B2 (en) Use of azapaullones for preventing and treating pancreatic autoimmune disorders
JP2021503486A5 (cg-RX-API-DMAC10.html)
KR20180101228A (ko) 신경세포 분화용 배지 조성물 및 상기 배지 조성물을 이용한 체세포로부터 신경세포로의 분화 방법
US20230364153A1 (en) Method for direct reprogramming from somatic cells into pancreatic beta cells by using microrna, and differentiation composition
JP7041877B2 (ja) チエノ[2,3-b]ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
EP2871181B1 (en) Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues
JP2022548162A (ja) ポンペ病を処置する方法